A compound of Formula 1: A-L-B Formula 1 or a pharmaceutically acceptable salt thereof, wherein: A is a dicarbonyl sequestering moiety, wherein A is a substituted aryl group of Formula 3: wherein two or more of R 7 -R 11 are independently selected from -NH 2, -NHR 1, -NR 1 R 1, -C 1-6 alkylene-NH 2, -C 1-6 alkylene-NHR 1, -O-NH 2, -O-NHR 1, -C 1-6 alkylene-O-NH 2, -C 1-6 alkylene-O-NHR 1, -NHCOR 1, -NR'-NHR', -C 1-6 alkylene -NR'-NHR'; and the remaining groups R 7 -R 11 are independently selected from -H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl,-halogen, -C 1-6 alkylene-OH, -C 1-6 alkylene-O-R 1, -CO 2 H, -C 1-6 alkylene-CO 2 H, -CO 2 R 1, -C 1-6 alkylene-CO 2 R 1, -C 1-6 alkylene-O-C -R 1, -CH -C -R 1, -C 1-6 alkylene-CH -C -R 1, -CHO, -C -R 1, -C NH 2, -C NHR 1, -SO 2 NH 2 and -SO 2 NHR 1; and each R 1 is independently selected from -C 1-6 alkyl, -C 2-6 alkenyl and -C 2-6 alkynyl; and each R' is independently selected from -H and -C 1-6 alkyl; L is a linker moiety of Formula 6: -(Z 1) m -X 1 -(Z 2) t - Formula 6 wherein Z 1 and Z 2 are independently selected from O, NR 12, NR 12 -C, C NR 12, O-C, C -O and S; R 12 is selected from -H and -C 1 -C 6 alkyl; m and t are independently selected from o or 1; X 1 is selected from C 1 -C 30 alkylene, C 2 -C 30 alkenylene, C 2 -C 30 alkynylene and C 3 -C 30 cycloalkylene; and B is a mitochondrial targeting moiety; wherein B is a triphenylphosphonium cation. A is a dicarbonyl sequestering moiety, wherein A is a substituted aryl group of Formula 3: wherein two or more of R 7 -R 11 are independently selected from -NH 2, -NHR 1, -NR 1 R 1, -C 1-6 alkylene-NH 2, -C 1-6 alkylene-NHR 1, -O-NH 2, -O-NHR 1, -C 1-6 alkylene-O-NH 2, -C 1-6 alkylene-O-NHR 1, -NHCOR 1, -NR'-NHR', -C 1-6 alkylene -NR'-NHR'; and the remaining groups R 7 -R 11 are independently selected from -H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl,-halogen, -C 1-6 alkylene-OH, -C 1-6 alkylene-O-R 1, -CO 2 H, -C 1-6 alkylene-CO 2 H, -CO 2 R 1, -C 1-6 alkylene-CO 2 R 1, -C 1-6 alkylene-O-C -R 1, -CH -C -R 1, -C 1-6 alkylene-CH -C -R 1, -CHO, -C -R 1, -C NH 2, -C NHR 1, -SO 2 NH 2 and -SO 2 NHR 1; and each R 1 is independently selected from -C 1-6 alkyl, -C 2-6 alkenyl and -C 2-6 alkynyl; and each R' is independently selected from -H and -C 1-6 alkyl; wherein two or more of R 7 -R 11 are independently selected from -NH 2, -NHR 1, -NR 1 R 1, -C 1-6 alkylene-NH 2, -C 1-6 alkylene-NHR 1, -O-NH 2, -O-NHR 1, -C 1-6 alkylene-O-NH 2, -C 1-6 alkylene-O-NHR 1, -NHCOR 1, -NR'-NHR', -C 1-6 alkylene -NR'-NHR'; and the remaining groups R 7 -R 11 are independently selected from -H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl,-halogen, -C 1-6 alkylene-OH, -C 1-6 alkylene-O-R 1, -CO 2 H, -C 1-6 alkylene-CO 2 H, -CO 2 R 1, -C 1-6 alkylene-CO 2 R 1, -C 1-6 alkylene-O-C -R 1, -CH -C -R 1, -C 1-6 alkylene-CH -C -R 1, -CHO, -C -R 1, -C NH 2, -C NHR 1, -SO 2 NH 2 and -SO 2 NHR 1; and each R 1 is independently selected from -C 1-6 alkyl, -C 2-6 alkenyl and -C 2-6 alkynyl; and each R' is independently selected from -H and -C 1-6 alkyl; each R 1 is independently selected from -C 1-6 alkyl, -C 2-6 alkenyl and -C 2-6 alkynyl; and each R' is independently selected from -H and -C 1-6 alkyl; L is a linker moiety of Formula 6: -(Z 1) m -X 1 -(Z 2) t - Formula 6 wherein Z 1 and Z 2 are independently selected from O, NR 12, NR 12 -C, C NR 12, O-C, C -O and S; R 12 is selected from -H and -C 1 -C 6 alkyl; m and t are independently selected from o or 1; X 1 is selected from C 1 -C 30 alkylene, C 2 -C 30 alkenylene, C 2 -C 30 alkynylene and C 3 -C 30 cycloalkylene; and wherein Z 1 and Z 2 are independently selected from O, NR 12, NR 12 -C, C NR 12, O-C, C -O and S; R 12 is selected from -H and -C 1 -C 6 alkyl; m and t are independently selected from o or 1; X 1 is selected from C 1 -C 30 alkylene, C 2 -C 30 alkenylene, C 2 -C 30 alkynylene and C 3 -C 30 cycloalkylene; and B is a mitochondrial targeting moiety; wherein B is a triphenylphosphonium cation.